Polycomb complex protein

spinqualitylabelsall models Structure of a Bmi1 protein Show:Asymmetric Unit Biological Assembly Drag the structure with the mouse to rotate   Export Animated Image   Print3D Function B-cell-specific Moloney leukemia virus insertion site 1 (BMI1) is a ring finger protein that is component of a Polycomb group (PcG) multiprotein PRC1 complex, which epigenetically repress regulatory genes related to embryonic development and self-renewal of somatic stem-cells. The name come from the original identification of BMI1 as an oncogene cooperating with a myc gene in lymphomagenesis . It became clear that the Bmi1 protein is part of an E3 ubiquitin ligase complex (PRC1) and that this complex has an important role in gene regulation during development. Monoubiquitinated H2A is enriched on the inactive human female X-chromosome. The inactivation of one of the X-chromosome is responsible for “dosing” the X-chromosome expression, which leads to the physiological X expression levels in females similar to the X expression levels in males (which has only one X). BMI1 can bind to the promoter of HoxC13 gene to regulate it and also can regulate other Hox genes, which define axial patterning and segment identity. PcG PRC1 is responsible for chromatin remodeling and histone modification, mediating monoubiquitination of histone H2A at Lysine 119, rendering chromatin heritably changed in its expressibility. BMI1 regulates the E3 ubiquitin-protein ligase activity of RING1b, which is also a protein component of the PcG PRC1 complex. Structure BMI1 is a 37 kDa protein composed of three distinct regions: an N-terminal RING domain, a central domain and a C-terminal proline-serine rich domain involved in the regulation of protein stability . In vitro, an sufficient active E3 ubiquitin ligase is formed by the heterodimerization of BMI1 and RING1b via their N-terminal RING domains, represented in dark blue. The heterodimerization occurs by the wrapping of the N-terminal arm of Ring1b around a groove on the surface of Bmi1, which stabilizes the structure of Ring1b and greatly stimulates ligase activity. Is worth noting that RING-domains, such as the found in BMI1 and RING1b, are structurally stabilized through the binding of two zinc atoms, hence the BMI1/RING1b complex interacts with 4 Zinc atoms to the correct folding (Zn highlighted in magenta). X-ray crystallography shows prominent salt bridges being formed by the Bmi1/Ring1b pairs of Asp72/Arg70, Glu11/Lys112, Lys81/Glu48, and Thr41/Arg26 . However, in vivo, the PRC1 complex is composed of four core subunits: CBX (polycomb; CBX2/4/6/7/8), PCGF (polycomb group factors; PCGF1–6, being PCGF4 the BMI1), PHC (polyhomeotic homologues; PHC1/2/3) and RING E3 ligase (RING1A/B). The PCGF2/RING1b (being PCGF2 the MEL-18 protein) and BMI1/RING1b represent canonical PRC1 complex, while PCGF1, PCGF 3, PCGF5 and PCGF 6 form non-canonical PRC1 complexes when in pair with RING1a or RING1b. In the complex, BMI1 and RING1b form a heterodimer and only RING1b interacts with UbcH5c, which is a Ubiquitin Conjugating Enzyme E2. A RING-domain E3 is responsible for promoting the transfer of ubiquitin (Ub) from the active site of the E2 ubiquitin-conjugating enzyme to an acceptor lysine residue in the substrate. The PRC1 complex promote the monoubiquitination of histone H2A on lysine 119 (uH2A), which leads to the stalling of the RNA polymerase at the promotor of the monoubiquitinated gene, hence the transcription doesn't occur. How can the PRC1 complex promote such a epigenetic modification? The complex itself doesn't attach to a ubiquitin in any moment, instead PRC1 binds to a previously ubiquitin loaded E2 enzyme UbcH5c, then the complex binds to the duplex of DNA, in a non-sequence-specific manner, through a surface patch unique to the BMI1/RING1b RING–RING dimer. In the loaded UbcH5c to the right, you can see UbcH5c in yellow, polyubiquitin-C in violet and glycerol in cyan. Glycerol helps to prevent protein aggregates during folding. In the Bmi1/Ring1b-UbcH5c complex structure, you can see BMI1 in light-blue, RING1b in light-green and E2 in yellow. In the crystal structure of the Ring1B/Bmi1/UbcH5c PRC1 ubiquitylation module bound to the nucleosome core particle, you can see BMI1 in light-blue, RING1b attached to E2 in light-salmon and H2A in lime. The ubiquitination is a cascade of events, in which PRC1 takes part in the end. First, E1 activating enzyme receives the ubiquitin through the covalent attaching of the ubiquitin C terminus to a cysteine of the E1 through a thioester bond, only possible due to ATP hydrolysis. Then, the E1 ubiquitin conjugate binds to an E2, catalyzing the transfer of the ubiquitin onto the E2 active site cysteine, also by a thio ester bond. Finally, the E3 ligase brings together the loaded E2 and the substrate, catalyzing the transfer of ubiquitin from the active site cysteine of the E2 to the amino group of a lysine sidechain, forming an isopeptide bond . Therefore, the PRC1 complex promotes the transfer of the ubiquitin attached to E2 enzyme UbcH5c to the lysine 119 on histone H2A. Computational modelling suggests that the heterodimer BMI1/RING1b interacts with both nucleosomal DNA and an acidic patch on histone H4 to promote the specific monoubiquitination of H2A. Although non-intuitive, the H2A ubiquitination is dispensable for chromatin compaction but essential for maintaining repression of specific genes and for maintaining ES cells in a dedifferentiated state. The fact that uH2A is dispensable for chromatin compaction was found by the introduction of a catalytically inactive RING1B mutant into Ring1A-/- Ring1B conditional knockout embryonic stem (ES) cells . Cascade of reaction involved in the ubiquitination process. Substrate represent the lysine 119 of histone 2A. In humans, there are multiple E2 ubiquitin-conjugating enzymes, but only UbcH5 and UbcH6 interact with the BMI1/RING1b heterodimer and promote the monoubiquitination of histone H2A at Lysine 119. The subtype UbcH5c is capable of making more polyubiquitin chains then UbcH5a and UbcH5b, in contrast UbcH6 doesn't make polyubiquitin chains. The BMI1/RING1b heterodimer interface buries a total of 2500 Ų surface area from the two proteins while the UbcH5c/RING1b interface has only 507Ų. The discrepancy between the areas of interface is reflected in the low affinity interaction between BMI1/RING1b and UbcH5c (Buchwald et al, 2006). The RING1b-binding surface on UbcH5c consists of two loops (L4 and L7), as well as residues from the N-terminal a helix (a1). Representation of Bmi1/Ring1b-UbcH5c complex structure, with UbcH5c in grey, L4 in yellow, L7 in purple, Ring1b in light blue, and Bmi1 in orange. Salt bridges are formed between Lys4 and Lys8 from the a1 helix of UbcH5c (ULys4 and ULys8) with Asp56 on Ring1b (RAsp56) Interactions between Ring1b, in gray, and UbcH5c, in green, along the N-terminal a-helix. The sidechains involved are shown in stick format. Hydrogen-bond distances are given in angstroms. In the SPA motif of the UbcH5 (L7 residues USer94, UPro95, and UAla96), the sidechain hydroxyl of USer94 makes a hydrogen bond with the backbone carbonyl of RPro88 (from RING1b). Hydrophobic interactions between UPro95 and UAla96 with RIle53 and RPro88 help to stabilize the interaction between UbcH5 and RING1b. Canonical PRC1 such as BMI1/RING1b have intrinsically very low enzymatic activity compared with non-canonical PRC1, although there are only subtle differences between the structure of canonical and non-canonical complexes. Two charged helix alpha 3 residues present in a modeled BMI1 seems responsible for the low activity of BMI1/RING1b, K73 and D77 form a salt bridge that may limit efficient ubiquitin transfer. In a computational modeling, BMI1 K73 clashes sterically with Ubiquitin, which implies that K73 must move to allow Ub loaded E2 to bind in an activated conformation or that Ub adopts a less optimal position during monoubiquitination. Either of these events could provide an energy barrier, slowing transfer catalyzed by BMI1. The intrinsically low activity of the BMI1/RING1b is offset by a relatively favorable interaction between E3–E2-Ub and nucleosome substrate, resulting in a site-specific monoubiquitination efficient enough. The energy barrier may be responsible for increasing the fidelity of the transfer to the appropriate substrate. Also, canonical and non-canonical differ in targeting sub-units, target genomic loci, and genes expression regulation. The central domain of BMI1 forms an ubiquitin-like (UBL) domain, which is involved in protein-protein interactions, including interactions with the transcription factors E4F1, Zfp277 and the PLZF-RARA fusion protein. The best characterized binding partners of the UBL domain are the polyhomeotic proteins (PHC1, PHC2, PHC3). The UBL domain binds a short, 24 amino acid fragment, of PHC2 in a b-hairpin conformation. Also, UBL domain is involved in homo-oligomerization of BMI1. NMR and carbon detected NMR found that residues 30-51 are strongly conserved between PHC2, PHC1 and PHC3 suggesting that BMI1 interacts with the three members of the polyhomeotic family in a very similar manner and with similar affinities. Deletion of the corresponding motif abolished the interaction with BMI1. In the PHC2-BMI1 complex, PHC2 residues 33–47 adopt a beta-hairpin conformation in the complex, in greenyellow. The PHC2-BMI1 interaction involves an antiparallel b-sheet formed between the beta 2 strand of BMI1 UBL, in magenta, and the beta-hairpin of PHC2. The antiparallel b-sheet is stabilized by the hydrogen bonds between BMI1 Tyr163 and PHC2 Gly46. MEL18, BMI1 homolog, also binds to PHC2, but with slightly reduced affinity. All BMI1 residues involved in contacts with PHC2 are identical with MEL18 and strongly suggests very similar binding mode for MEL18–PHC2. The similarity is explained by the 60% sequence identity between UBL domain and MEL18. MEL18 is capable of biding to RING1b to form a PRC1 complex too, but the MEL18/RING1b complex is significantly less active than the BMI1/RING1b complex. Besides biding to PHC1-3, the UBL domain also has a propensity of forming homo-oligomers in solution. This tendency is probably due to one hydrophobic region of UBL domain, which mutation at Ile212 impairs homo-oligomerization of the BMI1–PHC2 complex and the homo-oligomerization of UBL domain itself. This suggests that the same hydrofobic region might be responsible for the oligomerization of the BMI1/RING1b complex, such as the PRC1 complex tetramer found in vitro. Proposed architecture of the PRC1 complex oligomer. Disease The bmi1 gene was first associated with lymphoma, in cooperation with the oncogene myc. BMI1-deficient fibroblasts and lymphocytes show high expression of the tumour suppressors p16 and p19Arf, which are encoded by ink4a locus. Conversely, overexpression of bmi1 allows fibroblast immortalization, downregulates expression of p16 and p19Arf and, leading to neoplastic transformation. The modulation of the ink4a expression probably is due to the ubiquitination of a H2A in the region, compacting the chromatin and downregulating the expression of p16 and p19Arf. The B- and T-cell lymphomas are highly dose-dependent phenotypes regarding bmi1 gene expression. The overexpression can lead to B- and T-cell lymphomas and partial reduction of Bmi1 leads to significant reduction in lymphoma formation and brain tumour formation. BMI1 is also associated with colon cancer, in which BMI1 activates WNT signaling mainly through the downregulation of IDAX expression. The BMI1 protein binds to the promoter of IDAX, a Wnt antagonist, and decreases it’s transcription. The WNT signaling pathway is very important in cell fate determination and tissue development and stem cell maintenance. Excessive activation of this pathway leads to tumorigenesis in several types of human cancers. According to The Cancer Genome Atlas Network, the WNT pathway is hyper-activated in over 90% of colon cancer. IDAX as a target from BMI1. In the left is shown that the BMI1 knockdown by short hairpin RNAs leads to the increased IDAX transcription in colon cancer cell lines. In the right is shown the binding of the BMI1 protein to the promoter of IDAX, analyzed by ChIP-PCR. BMI1 also inhibits the CDKN1A gene, an important inhibitor of the cellular cycle, promoting the cellular proliferation. The inhibition of CDKN1A gene is promoted when a lncRNA, FALEC (focally amplified long non-coding RNA on chromosome 1 gene), stabilizes BMI1. Conservation In Drosophila, the corresponding BMI1 variant (Psc) also cause low intrinsic E3 ligase activity, suggesting that it may be biologically important to closely regulate the catalytic rate of the canonical PRC1 complex. The residues forming the interface between the PCGFs and RING1B are highly conserved: of 18 residues in the interface region, only 2, both from helix alpha 1, differ between PCGF4 and PCGF5. Gene duplication in mammals has created a RING1b homologous, the RING1a protein, and the BMI1 homologous, the MEL18 protein. The homologous proteins have very high sequence similarity, but they appear to fulfil different functions. The alignment of RING1a sequences from several species reveals that part of the N-terminal sequence (aa 11–30) of RING1a is well conserved in RING1b. Supposedly, the RING1a also binds to BMI1 via their N-terminal RING domains. Sequence alignment of Ring-domain proteins in PRC1 with secondary structure indicated. Zn binding site I is highlighted in blue and Zn binding site II is highlighted in cyan. Check, as determined by ConSurfDB. You may read the explanation of the method and the full data available from ConSurf.

External resources

• BMI1 in Wikipedia

• Aggregated information about BMI1 protein in UniProt database
• Aggregated information about BMI1 gene in GeneCards database

https://drive.google.com/drive/folders/1l195aNuY6joOd74GKKxa-XWTRMBv_uWF?usp=sharing

Proteopedia Page Contributors and Editors (what is this?)

Ricardo Alberto Chiong Zevallos, Michal Harel, Jaime Prilusky